Home/Filings/4/0001104659-24-106064
4//SEC Filing

Wiley Matthew T. 4

Accession 0001104659-24-106064

CIK 0001720893other

Filed

Oct 2, 8:00 PM ET

Accepted

Oct 3, 9:55 PM ET

Size

7.0 KB

Accession

0001104659-24-106064

Insider Transaction Report

Form 4
Period: 2024-09-17
Transactions
  • Award

    Common Stock

    2024-09-17+21,25025,283 total
  • Sale

    Common Stock

    2024-10-03$0.55/sh6,272$3,45019,011 total
Footnotes (2)
  • [F1]The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through October 1, 2024 (the "PSUs"). On September 17, 2024, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 21,250 PSUs had been satisfied and 21,250 shares of common stock became issuable to the Reporting Person on October 1, 2024.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.

Issuer

BioXcel Therapeutics, Inc.

CIK 0001720893

Entity typeother

Related Parties

1
  • filerCIK 0001759703

Filing Metadata

Form type
4
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 9:55 PM ET
Size
7.0 KB